A recent study suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a leading health publication shows that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"People using these treatments need to be informed of the risk of rapid rebound weight gain when the therapy concludes," warns expert Dr. Susan Jebb.
This pace of regain means a return to original weight in about 18 months.
Comparing Treatments
The study, which reviewed 37 of studies involving thousands of participants, contrasted the results of these new drugs with conventional dieting.
Scientists point out that individuals who shed pounds through lifestyle changes alone usually experience a more gradual weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Doctors believe the mechanism of the injections is key to understanding the accelerated regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to hunger is uncontrolled, making excessive eating a significant risk."
An Ongoing Issue?
The NHS advise the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, given the significant potential of weight regain, the treatment should be considered long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "emphasize the chronic nature of obesity," akin to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the jabs report a intense return of hunger.
"It was like a switch flipping and you become starving," recalled a patient.
The struggle is worsened if individuals have not developed lasting lifestyle or habit changes during treatment.
Significant Use
Survey data suggest that millions of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
In conclusion, experts caution that while the jabs are powerful tools for weight loss, they are not a permanent fix and lasting health benefits likely depends on integrated behavioural support.